LB Pharmaceuticals Inc (NasdaqGM: LBRX)
Health Care · Pharmaceuticals · US
$48.21
+1.24% today · +175.3% 1Y
LB Pharmaceuticals Inc (NasdaqGM: LBRX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.54B and employs 49 people.
Over the last twelve months the share price has gained 175.3%, trading between 13.36 and 49.14.
Tweenvest scores LB Pharmaceuticals Inc across four factors: quality 29/100. Its strongest factor is quality.
LBRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.54B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.81
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $49.14
- 52-week low
- $13.36
- Avg volume (3M)
- —
- Shares outstanding
- 32.26M
- Employees
- 49
- Next earnings
- —
About LB Pharmaceuticals Inc
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
- ISIN
- US50180M1080
- Founded
- 2015
- Listed since
- Sep 11, 2025
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.